Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00005506

Trial Description

start of 1:1-Block title

Title

Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Radiotherapy with or without adjuvant chemotherapy represents an important column of modern
therapy in advanced squamous cell originated tumours of the head and neck. However to date
no studies are available which study the effectiveness of radiotherapy in patients with
resected small tumours (T1, T2) and concomitant ipsilateral metastasis of a single lymph
node (pN1) for general treatment recommendation. The present study is designed as
non-blinded, prospective, multicenter randomized controlled trial (RCT) for comparison of
overall-survival as primary clinical target in patients receiving radiation therapy vs.
patients without adjuvant radiation following curative intended surgery. Aim of the study is
to enroll 560 adult males and females for 1:1 randomization to one of the two treatment arms
(radiation/non-radiation. Secondary clinical endpoints are as follows: Incidence and time to
tumor relapse (locoregional relapse, lymph node involvement and metastatic spread), Quality
of life as reported by EORTC (QLQ-C30 with H&N 35 module) and time from operation to
orofacial rehabilitation.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Background

Prevailing curative intended therapeutic strategies combine radical resection of the tumor
mass with a safety margin followed by radiation of the original tumor site and adjacent
locoregional lymphatic drainage areas. To date selection of the individual therapeutic
pattern is essentially guided by pre- and post-therapeutic TNM staging parameters.
Exceptionally for advanced tumors postoperative radiotherapy and optional combination with
(radiosensitizing) chemotherapeutic agents is favorable and recommended. Interdisciplinary
guidelines stated the following detailed recommendations for application of adjuvant
radiation therapy:

- non in sano resection if reoperation is impossible (R1-, R2-status)

- primary tumor status > pT2 and pN2, pN3

- extranodular spread of the disease

- lymphangiosis carcinomatosa

- facultative: pN1 According to these recommendations postoperative radiotherapy of
advanced tumors is feasible while for small tumors indication for adjuvant therapy
depends on further parameters like the pN findings. Here verification of more than one
singular lymph node metastasis (pN2) leads to additional radiotherapy. In tumors with a
diameter less than 4 cm (T1, T2) and concomitant verification of a single lymph node
metastasis no explicit therapeutic recommendation is offered to date displaying
radiation an optional complement for these cases. Meta-Analysis revealed only a few
studies taking this special group of patients into account stating adjuvant
radiotherapy an additional risk factor for overall survival, however small patient
numbers, inhomogeneous group distribution and ambiguous risk factors exhibited a
significant bias.

The methodological key problems which had to be addressed in the protocol were the
following:

- extremely different treatment arms with strong preferences for one or the other therapy
arm

- low number of eligible patients per center

- Inclusion criterion (pN1) including a pathological diagnosis and surgical treatment
with possible differences

- Radiation treatment as one arm with special need for quality control Thus the idea of
presenting this paper is, to discuss how these specific issues were taken care of.

Methods/Design Study Design The study is designed as a non-blinded, prospective, randomized
controlled clinical trial.

Study objectives Objective of the clinical study will be the investigation of two different
patient collectives (irradiated/unirradiated) with pT1/2 primary and verification of a
singular ipsilateral lymph node metastasis in parallel design in order to evaluate a
possible significant benefit of radiation therapy. Investigation of further biological
parameters will be concomitantly performed to assess a possible prediction of tumor
progression and to evaluate surrogate markers of radioresistance. The following null
hypothesis forms the basis of the present study: Radiation therapy will have no influence on
the overall survival in patients with pT1/2, pN1 primary tumor. Secondary outcome variables
include incidence and time to tumor relapse (locoregional relapse, lymph node involvement
and metastatic spread), Quality of life as reported by EORTC (QLQ-C30 with H&N 35 module)
and time from operation to orofacial rehabilitation.

Patients

Males and females with histological verified diagnosis of a primary squamous cell carcinoma
of the oral cavity or the oropharynx are eligible. Inclusion criteria are as follows:

- maximum tumor diameter less than 4 cm in the pathohistological specimen irrespective of
histological grading (pT1 or pT2)

- concomitant histological verification of a singular ipsilateral lymph node metastasis
less than 3cm in diameter (pN1) without penetration of the lymph node´s capsule and
without presence of lymphangiosis carcinomatosa

- radical resection of the tumor within adequate resection margins (R0)

- written informed consent from the patient

- adequate performance status ECOG Index ≤ 2 Patients with an age less than 18 and
pregnant women are to be excluded. Further criteria of exclusion are reported drug
addiction or intake of remedies with potential influence on compliance or impaired
judgment. In addition patients with mental disorders or conceivable physical, familial
or job related embarrassments which may preclude the patient to realize the study
schedule. Moreover patients with physical impairment by inadequate treatment of
derailed diseases e.g. untreated diabetes mellitus or acute heart insufficiency
(ECOG-Index >2).

Study interventions Radiotherapy should begin within 6 weeks after the last surgical
intervention, whereas a minimal postoperative healing period of at least 8 days should be
respected. Causes for delay of intervention are to be documented. Application of
radiotherapy defines group 1 versus the non irradiated group (group 2).

Surgical treatment The primary is considered radically resected if macroscopic and
histologic evaluation approved resection margins without tumor residuals (R0 status). For
surgical proceeding a safety margin of at least 1cm is established. For surgical
considerations of lymph node resection the tumor localization is divided in level I (below
occlusional plane) and level II (above occlusional plane) respecting pre-, postcanine or
retromolar finding in addition. Classification of cervical regions follows the
recommendations of Robbins from 2002. Hence, the neck is divided into 6 different sections.

Ipsilateral N0 state of cervical lymph nodes Pre- and postcanine localized tumors of level I
require a selective neck dissection of the cervical level 1-3. In level I tumours of the
retromolar triangle selective neck dissection of ipsilateral level 1-5 is proceeded. In
level II tumors no selective neck dissection is considered.

Contralateral N0 state No neck dissection is performed Ipsilateral N1- N2 state For
retromolar localized level I tumors a modified radical neck dissection is performed. If the
tumor is localized pre- or postcanine intraoperative frozen sections of level 1 lymph nodes
are evaluated. Positive intraoperative results lead to modified radical resection of level
1-5 lymph nodes. In case of negative results resection of the lymph nodes within level 1-3
is affiliated. Negative instantaneous sections in level II tumors require no lymph node
dissection. All metastatic affection of level II-III lymph nodes necessitates modified
radical neck dissection.

Contralateral N1-N2 state Instantaneous section is performed for level 1 lymph nodes.
Modified radical neck dissection is performed in positive, resection of level 1-3 lymph
nodes is conducted in negative results. Metastases spread in level 2-3 lymph nodes acquire
modified radical neck dissection.

Lymph node therapy of midline tumors Midline tumors may require bilateral resection of lymph
node echelons at risk. Bilateral modified neck dissection is performed for staging purposes
if indicated. Contralateral lymph node dissection of the level 1-3 in precanine localized
tumors is mandatory.

Technical conditions and practical execution of radiation therapy Radiotherapy is performed
by photons of 4 to10 MeV or/and electrons of 6 to 15 MeV maximum energy. Individual 3
dimensional dose distribution calculation is mandatory and has to be made on the basis of a
postoperative native computer tomogram. All patients are to be treated while immobilized by
a custom made face mask made of thermoplast or equivalent. Clinical target volume definition
compasses the original tumor site with a safety margin of 2 cm in each direction.

Floor of mouth, anterior tongue Irradiation of the anterior two third of the tongue as well
as the anterior floor of mouth is irradiated by lateral opposing beams, while the maxilla is
separated by insertion of a bite block.

Oropharynx, buccal plane, soft palate confined to one side For tumors of the buccal plane,
the tonsilla, the soft palate and the retromolar triangle two types of planning target
volume may be applied.

In case of negative contralateral cervical nodes an ipsilateral target volume for the
primary is defined including the lymph nodes of group IB, IIA and IIB. Irradiation technique
recommended is a two wedge fields typically angulated by 90 to 120 degrees. The ipsilateral
node levels III-V are treated by an anterior portal down to clavicle. The contralateral neck
is spared.

Tumors of the lateral and dorsal pharyngeal wall and their lymphatic drainage (levels II,
III, IV and V) are irradiated bilaterally with opposing beams. Irrespective of technique
used 3 D conformal dose shaping is highly recommended.

Dosage and fractionation Target volume definition and dosage has to be performed according
to the rules of ICRU report 50. At the primary tumor site and at involved lymph node levels
a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled. At electively
irradiated volumes a total dose of 50.4 Gy in 28 fractions is scheduled. All fractions of
1.8 Gy each are given five times per week. In case of machine break down an additional
fraction per week is recommended with an at least 6 h interval between two fractions on the
same day or on Saturday. Total treatment duration (including planned/unplanned
interruptions) is to be documented in days. Any patient must be available for intent to
treat analysis.

Instead of the classical portal arrangements and dose distributions intensity modulated
radiotherapy using an inverse calculation algorithm may be used in experienced centers. Dose
constraints for normal tissues are at the discretion of the participating centers. Dose
specification according to the RTOG protocol H 0022 is recommended. Details are given in a
standard operation procedure.

Follow-Up Recruitment phase will be 4 years with physical examination, ECOG index, and
quality of life questionnaire will be performed 3, 6 and 12 months after end of radiation.
Further follow up will be performed annually up to 5 years to obtain sufficient clinical
data.

Randomization and Sample Size The present study setup consists of a two armed randomized
controlled trial (RCT) as primary study aim. Patients rejecting their participation to a
randomized approach and preference to a certain procedure (radiation/no radiation) will be
included into a prospective observational study after given informed consent. This parallel
constructed observational trial will be performed with a maximum of consistency to treatment
and observation compared to the RCT. In case of positive attendance the patients will be
randomized, stratified by the criteria of adequate lymph node therapy (yes/no) as formulated
by the DOESAK. Randomization to both groups (radiation group/control group) will be 1 to1.
Patients will be recruited over a period of 4 years and follow-up will be annually until the
trial ends, i.e. at least for 5 years for each patient. Sample size calculation will be
performed for the two-sided log rank test at a significance level of 5%. Assuming an
exponential distributed survival with survival probabilities after 5 years of 45% within the
control group and of 55% within the radiation group (results observed from the DOESAK
collective) and a drop-out rate of 5% per year, 280 patients per group are required to
detect a significant difference in overall survival with a power of 70%. In case of impaired
patient recruitment within the randomized trial, it is intended to recruit at least 280
patients per group in the observational study.

Analysis of RCT and observational trial

Initiation of this trial is only arguable with a realistic chance of statistical evaluation
of an adequate count of randomized patients. Hence an intermediate assessment of attendance
to randomization will be performed after the first and the second year of recruitment. If
less than 5% of patients agreed to randomization within the first and 10% within the second
year RCT will be stopped and the study is continued solely as observational trial (see table
1). Intermediate assessment is performed with presumption of accelerating involvement to
achieve a minimum of 20% randomized patients after the recruitment phase. As consequence to
the study design two different collectives (randomized collective/ collective with preferred
form of therapy) will exist. The following scenarios of analysis are possible:

1. If a sufficient number of patients was randomized, treatment comparison will be
performed within the randomized collective. The non-randomized collective will be used
to evaluate the external validity of observed treatment effects.

2. If no sufficient number of patients could be randomized, all recruited patients will be
analyzed. Descriptive comparison of treatment groups will be performed for all baseline
variables. All analyses will be performed with adjustment to baseline variables
affecting survival. Results have to be interpreted with respect to any group
differences in baseline variables.

Outcome measurements Primary clinical endpoint Overall survival Secondary clinical endpoints
Incidence of tumor relapse

- Time to occurrence of lymphatic metastases

- Time to occurrence of local relapse

- Time to occurrence of distant metastases

- Tumor related death due to local tumor progression or metastatic spread Life quality

- Time to provisional orofacial rehabilitation

- Time from operation to first intermediate prosthesis intake

- Time from operation to definitive prosthesis application

- Life Quality report (EORTC QLQ-C30 with H&N 35 module)

Overall survival will be evaluated in a Cox proportional hazard model with treatment and
adequate lymph node therapy (yes/no) as covariates. Further covariates may be considered if
they affect survival.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005506
  •   2013/12/06
  •   2009/08/24
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00964977  (ClinicalTrials.gov)
  •   DOESAK-pN1-108399  (Johannes Gutenberg University Mainz)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Oropharyngeal Cancer
  •   Oral Cancer
  •   Lymph Node Metastasis
  •   C10 -  Malignant neoplasm of oropharynx
  •   C00-C14 -  Malignant neoplasms of lip, oral cavity and pharynx
  •   C77 -  Secondary and unspecified malignant neoplasm of lymph nodes
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Radiation: Radiation therapy
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group), Control group receives no treatment
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Primary study object: overall survival; time frame: 9 years; The objective of the clinical study will be to investigate two different patient groups (irradiated/unirradiated) with pT1/2 primary and verification of a singular ipsilateral lymph node metastasis in parallel design in order to evaluate the possible benefit of radiation therapy. The following null hypothesis forms the basis of the present study: Radiation therapy will have no influence on the overall survival in patients with pT1/2, pN1 primary tumor. First patients will be observed for 9 years, last patient in will be followed-up for 5 years.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Time to occurrence of local relapse; time frame: 2, 3 and 6 months; 1 year to 9 years; Recruitment phase will be 4 years and follow up 5 years. First patients will be observed following the schedule above for 9 nine years, last patients will be observed for a minimum of 5 years.
- Time to lymphatic metastasis; time frame: 2, 3 and 6 months, 1 year to 9 years; Recruitment phase will be 4 years and follow up 5 years. First patients will be observed following the schedule above for 9 nine years, last patients will be observed for a minimum of 5 years.
- Time to occurence of distant metastasis; time frame: 2,3,6 months and 1 year to 9 years annually; Recruitment phase will be 4 years and follow up 5 years. First patients will be observed following the schedule above for 9 nine years, last patients will be observed for a minimum of 5 years.
- Quality of Life; time frame: after 6 months, 1 year and annually till end of study; QLQ 30 and HN35 Questionnaire will be assessed after 6 months and annually Course of provisional and definite orofacial rehabilitation will be assessed in each meeting

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Netherlands
  •   Switzerland
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2009/10/31
  •   560
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- histological diagnosis of a primary squamous cell carcinoma of the oral cavity or the
oropharynx

- maximum tumor diameter less than 4 cm in the pathohistological specimen irrespective
of histological grading (pT1 or pT2)

- concomitant histological verification of a singular ipsilateral lymph node metastasis
less than 3cm in diameter (pN1) without penetration of the lymph node´s capsule and
without presence of invasion of lymphatic vessels (lymphangiosis carcinomatosa)

- radical resection of the tumor within adequate resection margins (R0)

- written informed consent from the patient

- adequate performance status ECOG Index ≤ 2

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- an age less than 18 years old

- pregnant women

- reported drug addiction

- intake of remedies with potential influence on compliance or impaired judgment

- patients with mental disorders or conceivable physical, familial or job related
embarrassments which may preclude the patient to realize the study schedule

- inadequate performance status ECOG Index > 2

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Johannes Gutenberg University Mainz
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Deutsche Krebshilfe e.V., Bonn (Germany)
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Wilfried Wagner, MD, DMD, PHD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Bilal Al-Nawas, MD,DMD,PHD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Homepage Deutsche Krebshilfe
  •   Study Homepage
  •   Moergel M, Jahn-Eimermacher A, Krummenauer F, Reichert TE, Wagner W, Wendt TG, Werner JA, Al-Nawas B. Effectiveness of adjuvant radiotherapy in patients with oropharyngeal and floor of mouth squamous cell carcinoma and concomitant histological verification of singular ipsilateral cervical lymph node metastasis (pN1-state)--a prospective multicenter randomized controlled clinical trial using a comprehensive cohort design. Trials. 2009 Dec 23;10:118.; 20028566
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   3
  •   2013/12/01
* This entry means the parameter is not applicable or has not been set.